Table 3.

Comparison of clinical characteristics between the poor clinical outcome and good clinical outcome groups after 12 months.

	Poor clinical outcome (n = 12)	Good clinical outcome (n = 40)	P value
Age, years, (mean ± SD)	37.67 ± 12.42	37.00 ± 13.26	0.878
Male	4 (33.33)	31 (77.50)	0.004
GCS score			0.512
13–15	6 (50.00)	22 (55.00)
5–12	6 (50.00)	16 (40.00)
3–4	0 (0.00)	2 (5.00)
Abnormal electroencephalography	4 (33.33)	18 (45.00)	0.473
CSF detection
White cell count per mm3, (mean ± SD)	19.42 ± 16.06	32.50 ± 56.76	0.449
Protein concentration, mg/dL, (mean ± SD)	0.68 ± 0.67	0.53 ± 0.55	0.184
Positive antibody in CSF (%)	12(100.00)	40 (100.00)	NA
Positive antibody in serum, (%)	4(33.33)	9(22.50)	0.447
ICU admission	5 (41.67)	15(37.50)	0.646
Central hypoventilation	6 (50.00)	5 (12.50)	0.065
Days of immunotherapy from disease onset, mean (mean ± SD)	23.92 ± 10.14	26.05 ± 21.01	0.736
First-line therapy, (%)
Steroids alone	1 (8.33)	7 (17.50)	0.886
Intravenous immunoglobulin alone	1 (8.33)	8 (20.00)	0.663
Combination	10 (83.33)	25 (62.50)	0.177
Second-line therapy, (%)
Rituximab	0 (0.00)	2 (5.00)	1.000
Cyclophosphamide	1 (8.33)	5 (12.50)	0.651
Prodrome symptoms, (%)
Fever	3 (25.00)	21 (52.50)	0.113
Headache	6 (50.00)	18 (45.00)	1.000
Dizziness	3 (25.00)	5 (12.50)	0.366
Clinical symptoms, (%)
Abnormal behavior	5 (41.67)	24 (60.00)	0.262
Movement disorder	0 (0.00)	2 (5.00)	1.000
Speech disorder	2 (16.67)	5 (12.50)	0.656
Seizures	6 (50.00)	19 (47.50)	0.879
Sleep disturbance	0 (0.00)	4 (50.00)	0.562
Memory disorder	1 (8.33)	8 (20.00)	0.666
Altered consciousness	8 (66.67)	20 (50.00)	0.439
Central hypoventilation	6 (50.00)	9 (22.50)	0.065
MRI findings, (%)			0.064
Normal	4 (33.33)	11 (27.50)
Lesions in cerebral cortex	3 (25.00)	22 (55.00)
Lesions in white matter	3 (25.00)	1 (2.50)
Lesions in thalamus	0 (0.00)	2 (5.00)
Lesions in Leptomeningea	2 (16.67)	4 (10.00)